Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice

Journal of Clinical Investigation

Volumn 123, Issue 4, 2013, Pages 1741-1749

  Look, Michael ^a   Stern, Eric ^a   Wang, Qin A ^a   DiPlacido, Leah D ^b   Kashgarian, Michael ^b   Craft, Joe ^b   Fahmy, Tarek M ^a  

^a Yale University   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; MACROGOL; MYCOPHENOLIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; FEMALE; GLOMERULONEPHRITIS; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTOPENIA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; SURVIVAL; SYNTHESIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; BLOOD UREA NITROGEN; CELLS, CULTURED; CYCLODEXTRINS; DENDRITIC CELLS; FEMALE; KIDNEY; LACTIC ACID; LIPOSOMES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED BALB C; MYCOPHENOLIC ACID; NANOCAPSULES; NANOCONJUGATES; POLYETHYLENE GLYCOLS; POLYMERS; PROTEINURIA; T-LYMPHOCYTES; TISSUE DISTRIBUTION;

EID: 84875822264     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI65907     Document Type: Article

References (46)

1. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929-939.
2. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: Positive feedback in systemic autoimmune disease. Nat Rev Immunol. 2001;1(2):147-153.
3. Teichmann LL, Ols ML, Kashgarian M, Reizis B, Kaplan DH, Shlomchik MJ. Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity. 2010;33(6):967-978.
4. Bennett L, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197(6):711-723.
5. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity. 2003;19(2):225-234.
6. Saxena R, Mahajan T, Mohan C. Lupus nephritis: Current update. Arthritis Res Ther. 2011;13(5):240.
7. Contreras G, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004; 350(10):971-980.
8. Petri M. Cyclophosphamide: New approaches for systemic lupus erythematosus. Lupus. 2004; 13(5):366-371.
9. Chatham WW, Kimberly RP. Treatment of lupus with corticosteroids. Lupus. 2001;10(3):140-147.
10. de Achaval S, Suarez-Almazor ME. Treatment adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and systemic lupus erythematosus. Int J Clin Rheumtol. 2010;5(3):313-326.
11. Merrill JT, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(10):3077-3087.
12. Rovin BH, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215-1226.
13. Navarra SV, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-731.
14. Blanco E, Hsiao A, Mann AP, Landry MG, Meric-Bernstam F, Ferrari M. Nanomedicine in cancer therapy: Innovative trends and prospects. Cancer Sci. 2011;102(7):1247-1252.
15. Look M, Bandyopadhyay A, Blum JS, Fahmy TM. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv Drug Deliv Rev. 2010; 62(4-5):378-393.
16. Scindia Y, Deshmukh U, Thimmalapura PR, Bagavant H. Anti-alpha8 integrin immunoliposomes in glomeruli of lupus-susceptible mice: A novel system for delivery of therapeutic agents to the renal glomerulus in systemic lupus erythematosus. Arthritis Rheum. 2008;58(12):3884-3891.
17. Serkova NJ, et al. Renal inflammation: Targeted iron oxide nanoparticles for molecular MR imaging in mice. Radiology. 2010;255(2):517-526.
18. Stern E, et al. Combination delivery of TGF-® inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumor immunotherapy. Nat Mater. 2012;11(10):895-905.
19. Kabanov AV, Vinogradov SV. Nanogels as pharmaceutical carriers: Finite networks of infinite capabilities. Angew Chem Int Ed Engl. 2009;48(30):5418- 5429.
20. Maurer N, Fenske DB, Cullis PR. Developments in liposomal drug delivery systems. Expert Opin Biol Ther. 2001;1(6):923-947.
21. Hillery AM, Lloyd AW, Swarbrick J. Drug Delivery and Targeting for Pharmacists and Pharmaceutical Scientists. New York, New York, USA: Taylor and Francis; 2001.
22. Appel GB, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103-1112.
23. Dooley MA, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886-1895.
24. Elbarbry FA, Shoker AS. Liquid chromatographic determination of mycophenolic acid and its metabolites in human kidney transplant plasma: Pharmacokinetic application. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;859(2):276-281.
25. Sawhney AS, Pathak CP, Hubbell JA. Bioerodible hydrogels based on photopolymerized poly(ethylene glycol)-co-poly(〈-hydroxy acid) diacrylate macromers. Macromolecules. 1993;26:581-587.
26. Linterman MA, et al. Follicular helper T cells are required for systemic autoimmunity. J Exp Med. 2009;206(3):561-576.
27. Odegard JM, et al. ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J Exp Med. 2008; 205(12):2873-2886.
28. Masutani K, et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum. 2001;44(9):2097-2106.
29. Wofsy D, Seaman WE. Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4. J Exp Med. 1985;161(2):378-391.
30. Wofsy D, Seaman WE. Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. J Immunol. 1987; 138(10):3247-3253.
31. Bekar KW, et al. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum. 2010; 62(8):2443-2457.
32. Li Y, et al. B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL/lpr mice. J Immunol. 2008;181(5):2961-2972.
33. Ahuja A, Shupe J, Dunn R, Kashgarian M, Kehry MR, Shlomchik hMJ. Depletion of B cells in murine lupus: Efficacy and resistance. J Immunol. 2007; 179(5):3351-3361.
34. Ramos MA, et al. Modulation of autoantibody production by mycophenolate mofetil: Effects on the development of SLE in (NZB x NZW)F1 mice. Nephrol Dial Transplant. 2003;18(5):878-883.
35. Lui SL, et al. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice. Lupus. 2002; 11(7):411-418.
36. Mehling A, Grabbe S, Voskort M, Schwarz T, Luger TA, Beissert S. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol. 2000;165(5):2374-2381.
37. Lagaraine C, Hoarau C, Chabot V, Velge-Roussel F, Lebranchu Y. Mycophenolic acid-treated human dendritic cells have a mature migratory phenotype and inhibit allogeneic responses via direct and indirect pathways. Int Immunol. 2005;17(4):351-363.
38. Shirali AC, et al. Nanoparticle delivery of mycophenolic acid upregulates PD-L1 on dendritic cells to prolong murine allograft survival. Am J Transplant. 2011;11(12):2582-2592.
39. Ginzler EM, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005;353(21):2219-2228.
40. Jacob CO, et al. Pivotal role of Stat4 and Stat6 in the pathogenesis of the lupus-like disease in the New Zealand mixed 2328 mice. J Immunol. 2003; 171(3):1564-1571.
41. Steinmetz OM, et al. CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis. J Immunol. 2009;183(7):4693-4704.
42. Peng SL, Moslehi J, Craft J. Roles of interferon-gamma and interleukin-4 in murine lupus. J Clin Invest. 1997;99(8):1936-1946.
43. Ichinose K, et al. Cutting edge: Calcium/calmodulin-dependent protein kinase type IV is essential for mesangial cell proliferation and lupus nephritis. J Immunol. 2011;187(11):5500-5504.
44. Ziswiler R, Steinmann-Niggli K, Kappeler A, Daniel C, Marti HP. Mycophenolic acid: A new approach to the therapy of experimental mesangial proliferative glomerulonephritis. J Am Soc Nephrol. 1998; 9(11):2055-2066.
45. Suana AJ, et al. Single application of low-dose mycophenolate mofetil-OX7-immunoliposomes ameliorates experimental mesangial proliferative glomerulonephritis. J Pharmacol Exp Ther. 2011; 337(2):411-422.
46. Lund J, Sato A, Akira S, Medzhitov R, Iwasaki A. Toll-like receptor 9-mediated recognition of herpes simplex virus-2 by plasmacytoid dendritic cells. J Exp Med. 2003;198(3):513-520.